Chapter 33, Ep 2 of 5: C. diff Recurrence Toolkit

What this episode covers

Recurrence is the dominant management problem in C. diff, and this episode organizes the entire toolkit around a single mechanism: the spore. Surviving spores germinate once the antibiotic stops, so every tool either keeps colonic drug above the killing threshold across successive germination waves or restores the commensal community that denies spores a niche. The drug you reach for depends on what was used first, the structural taper-and-pulse pattern matters more than the molecule, and after two or more recurrences the strategy shifts from antibiotics to microbiome restoration. Bezlotoxumab and prophylaxis close the loop in the right patients.   Topics covered The spore-germination cycle behind recurrence Fidaxomicin for a first recurrence Extended-pulse fidaxomicin dosing Vancomycin tapered-pulsed dosing Bezlotoxumab host-immunity layer Microbiome restoration after multiple recurrences Live biotherapeutics Rebyota and Vowst Oral vancomycin prophylaxis   Key decisions After a first recurrence in a patient treated with vancomycin or metronidazole, switch to fidaxomicin, using extended-pulse dosing in older patients with a prior episode and coverage. After a first recurrence in a patient treated initially with fidaxomicin, use vancomycin tapered-pulsed dosing rather than repeating a flat ten-day course, because the temporal exposure pattern is what prevents recurrence. Add bezlotoxumab ten milligrams per kilogram as a single infusion during the antibiotic course in patients with recurrence risk factors, and never substitute it for the antibiotic or use it as monotherapy. After two or more recurrences, shift from repeat antibiotics, which sustain only about thirty percent cure, to microbiome restoration, which reaches eighty to ninety percent sustained cure. Give the standardized live biotherapeutic products after a completed antibiotic course: rectal single-dose Rebyota or oral spore Vowst, endorsed by ACG for the second or subsequent recurrence. Offer oral vancomycin prophylaxis during future antibiotic exposure only to patients with prior CDI, because the benefit does not extend to patients without a prior episode.   For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com. Questions or feedback: [email protected].

PodParley-generated summary based on available episode metadata and transcript content.